- Principal Health Economist - Rachel Hunter
- Junior Health Economist - Ekaterina Kuznetsova
Routinely in the UK, major funding programmes like the NIHR Health Technology Assessment Programme request that considerations on the costs, alongside the effectiveness, of new interventions are incorporated in the design and development of clinical trials.
The comparative evaluation of the costs and outcomes of alternative programmes or interventions is generally known as cost-effectiveness analyses. Information about the cost-effectiveness of new interventions is used to inform decision making by organisations such as the NHS National Institute for Health and Clinical Excellence (NICE).
The CCTU will assess the need of each trial for a health economics component. When appropriate, we will provide expert advice on health economics issues to academics and clinicians who are developing proposals for funding, and we will undertake cost-effectiveness analyses for funded projects requiring a health economic evaluation.